| 呼改凤,呼朝,杨劲.吉非替尼联合中医辨证论治疗对晚期肺腺癌患者EGFR、BRAF的影响[J].中国药事,2020,34(7):840-844 |
| 吉非替尼联合中医辨证论治疗对晚期肺腺癌患者EGFR、BRAF的影响 |
| The Effect of Gefitinib Combined with Syndrome Differentiation of Traditional Chinese Medicine on EGFR, BRAF in Patients with Advanced Lung Adenocarcinoma |
| |
| DOI：10.16153/j.1002-7777.2020.07.018 |
| 中文关键词: 吉非替尼 中医辨证论 晚期肺腺癌 表皮生长因子受体 B型原癌基因丝氨酸/苏氨酸蛋白激酶 |
| 英文关键词: gefitinib syndrome differentiation of traditional Chinese medicine advanced lung adenocarcinoma epidermal growth factor receptor B proto-oncogene serine/threonine protein kinase |
| 基金项目: |
|
| 摘要点击次数: 375 |
| 全文下载次数: 114 |
| 中文摘要: |
| 目的：探讨吉非替尼联合中医辨证论治疗对晚期肺腺癌患者表皮生长因子受体(EGFR)、B型原癌基因丝氨酸/苏氨酸蛋白激酶(BRAF)的影响。方法：选取2016年1月至2018年1月本院晚期肺腺癌患者100例，依据随机数字表分为吉中组和吉尼组，每组50例，吉尼组给予吉非替尼治疗，吉中组在此基础上给予中医辨证论治疗，比较两组肿瘤标志物(EGFR、BRAF)、治疗疗效、不良反应、生存情况。结果：吉中组和吉尼组治疗后EGFR、BRAF明显低于治疗前，吉中组治疗后EGFR、BRAF明显低于吉尼组，差异有统计学意义(P＜0.05)；吉中组治疗有效率明显高于吉尼组，差异有统计学意义 (P＜0.05)；吉中组和吉尼组不良反应发生率比较，差异无统计学意义(P＞0.05)；随访12个月后， 吉中组生存率明显高于吉尼组，差异有统计学意义(P＜0.05)。结论：吉非替尼联合中医辨证论治疗可有效降低晚期肺腺癌患者EGFR、BRAF水平，有利于提高临床疗效及生存预后，且安全性好，值得临床推广。 |
| 英文摘要: |
| Objective: To discuss the effect of gefitinib combined with syndrome differentiation of traditional Chinese medicine on the epidermal growth factor receptor (EGFR), B proto-oncogene serine/threonine protein kinase (BRAF) in patients with advanced lung adenocarcinoma. Methods: 100 patients with advanced lung adenocarcinoma in our hospital from January 2016 to January 2018 were selected, and they were divided into Jizhong group and gefitinib group at random according to the number table with 50 cases in each group. Gefitinib group was treated with gefitinib, Jizhong group was treated with syndrome differentiation of traditional Chinese medicine on the basis of the gefitinib group. EGFR, BRAF, the therapeutic effects, adverse reactions and the survival situations of the two groups were compared. Results: EGFR and BRAF in Jizhong group and gefitinib group after treatment were found significantly lower than those before treatment, EGFR and BRAF in Jizhong group after treatment were found significantly lower than those in gefitinib group, and the difference was statistically significant (P＜0.05). The effective rate of treatment in Jizhong group was significantly higher than that in gefitinib group with a statistically significant difference (P＜0.05). There was no significant difference in the incidence of adverse reactions between Jizhong group and gefitinib group (P＞0.05). After 12 months of follow-up, the survival rate of Jizhong group was significantly higher than that of gefitinib group, and the difference was statistically significant (P＜0.05). Conclusion: The treatment of gefitinib combined with syndrome differentiation of traditional Chinese medicine can effectively reduce EGFR and BRAF levels in patients with advanced lung adenocarcinoma and will improve the therapeutic efficacy and survival prognosis. Besides, it is safe and worthy of further clinical promotion. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |